Novaliq GmbH , a Germany based specialty pharmaceutical company, transforms poorly soluble drugs into effective therapeutics for ophthalmology and derma, using a novel and disruptive drug delivery platform. Novaliq’s most advanced product is NovaTears® with CE-marking based on Novaliq’s proprietary EyeSol® technology and is marketed under the brand name EvoTears® in Europe.


Bernhard Guenther

Bernhard Günther

Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in the field of ocular biopharmaceutics and medical devices.

View Full Profile